Fig. 4: G100 enhances adoptive cell therapy.

a Schematic of tumor inoculation, adoptive transfer, and G100 administration. Female C57BL/6 mice (n = 8–10/group) were inoculated with B16/OVA or B16 cells (flank, subcutaneously) on Day 0. Once tumors became palpable (averaged 5 mm in diameter), tumor-bearing mice received adoptive transfer of CD8 T cells isolated from OT-I or PMEL mice, respectively, and given intratumoral G100 that was continued twice weekly until observation of complete tumor regression or euthanized due to tumor burden. b Tumor size and c survival plots for mice inoculated with B16/OVA cells and received adoptive transfers of OT-I T cells. d Tumor size and e survival plots for mice inoculated with B16 cells and received adoptive transfers of PMEL T cells. Tumor sizes were plotted as average tumor volume ± SEM. Death was recorded as a result of natural death and death defined by euthanasia criteria. f Representative flow cytometry diagrams of tumor-infiltrating T cells, collected 3 days post-ACT and two G100 injections, with average percent CD8 and CD4 T cells of total CD3 T cells per group indicated, respectively, within the diagrams. Individual percent g CD8 and h CD4 T cells of total CD3 T cells per mouse per group are graphed. An average of 2 × 10⁶ events per sample were collected for analysis. Gating strategy: Singlets (SSC-A = SSC-H), lymphocytes (FSC-A vs. SSC-A), live cells (fixable live/dead stain negative), T cells (CD3⁺ B220⁻), CD8 T cells (CD8⁺ CD4⁻) and CD4 T cells (CD8⁻ CD4⁺).Data are representative of at least two independent experiments (**p < 0.01, ***p < 0.001).